Show/Hide Menu

Scientific research expertise

MorphoSys is pushing the boundaries of antibody generation in its attempts to generate antibody drugs with superior development potential and product characteristics. Our scientists are antibody experts, but our core capabilities can be applied to a broad range of molecules and drug classes. With more than 20 years’ experience in drug discovery and development, MorphoSys can give therapeutic projects a head start.

Discovery, Alliances and Technologies
Dr. Markus Enzelberger – Head of Discovery, Alliances and Technologies

The Discovery, Alliances and Technologies department focuses on the progress of MorphoSys’s therapeutic programs with partnered and proprietary compounds. Thanks to their successful execution of projects with MorphoSys’s pharmaceutical and biotech partners, the Company is well-known in the industry as a reliable and high-quality collaboration partner. The department advances the development of new technologies in order to maintain technological leadership in the antibody sector. Just recently, lanthipeptides were added as a novel drug class to the portfolio. The team’s scientific knowledge and MorphoSys’s technologies are also the source of the in-house discovery of novel compounds.

Protein Sciences
Dr. Ralf Ostendorp – Head of Protein Sciences

Protein Sciences is responsible for all production- and analytics-related tasks within MorphoSys’s customer projects and its proprietary discovery and drug development programs. The declared aim is to develop the best production method and route of administration for a program. With their expertise in protein production and characterization, this scientific team acts as a guarantor for the speed and quality of MorphoSys’s partnered and proprietary drug development programs.

Preclinical Development
Dr. Stefan Steidl - Head of Preclinical Development

The preclinical stage of drug development requires the application of rigorous scientific standards and expertise to effectively advance drug candidates from the laboratory to clinical trials. MorphoSys has the scientific expertise and experience required for the design, execution, and documentation of studies during all phases of preclinical drug development. The Preclinical Development team takes care of the comprehensive characterization of the proprietary lead compounds in terms of pharmacology, toxicology and pharmacokinetics.

Meet us at the following conferences

Wed-Sat
11-14
'15
Mar
Mar

2nd International Conference on Label-Free Technologies

Boston, USA
Sat-Wed
18-22
'15
Apr
Apr

AACR Annual Meeting 2015

Philadelphia, PA, USA
Mon-Thu
04-07
'15
May
May

PEGS Boston

Boston, USA
Fri-Tue
29-02
'15
May
Jun

ASCO Annual Meeting

Chicago, IL, USA
Thu-Sun
11-14
'15
Jun
Jun

EHA Congress

Vienna, Austria
Mon
15
'15
Jun

BIO Convention

Philadelphia, USA
Wed-Fri
16-18
'15
Sep
Sep

GPCRs: Beyond Structure Toward Therapy

Prato, Italy
Mon-Wed
21-23
'15
Sep
Sep

Monash mAb Conference

Prato, Italy
Mon-Wed
28-30
'15
Sep
Sep

Human Antibodies and Hybridomas (HAH) 2015

Lausanne, Switzerland
Thu-Fri
01-02
'15
Oct
Oct

Biacore User Meeting

Berlin, Germany
Mon-Fri
02-06
'15
Nov
Nov

PEGS Europe

Lisbon, Portugal
Sat
05
'15
Dec
ASH Annual Meeting 2015
Orlando, OR, USA
Mon-Thu
07-10
'15
Dec
Dec

Antibody Engineering & Therapeutics

San Diego, CA, USA
Thu
10
'16
Mar

Leerink Partners Annual Emerging Biotech Conference

Snowbird, UT, USA
Sat-Wed
16-20
'16
Apr
Apr

AACR Annual Meeting 2016

New Orleans, LA, USA
Sun-Tue
17-19
'16
Apr
Apr

9th Proteins and Antibodies Congress

London, UK
Sun-Thu
24-28
'16
Apr
Apr

8th International Congress of Antibodies

Dalian, China
Mon-Fri
25-29
'16
Apr
Apr

PEGS 2016

Boston, USA
Fri-Mon
03-06
'16
Jun
Jun

ASCO 2016

Chicago, Illinois, USA
Sat-Tue
03-06
'16
Dec
Dec

ASH Annual Meeting 2016

San Diego, CA, USA
Mon-Fri
09-13
'17
Jan
Jan

PepTalk

San Diego, CA, USA
Mon-Tue
06-07
'17
Mar
Mar

Biologics & Biosimilars Congress

Berlin, Germany
Mon-Fri
13-17
'17
Nov
Nov

PEGS Europe

Lisboa, Portugal

Related Links